Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM3 | Q86V86 | 3/20 | 0.51 |
| ▸ | PIM1 | P11309 | 3/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.51 |
| ▸ | FLT3 | P36888 | 2/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.51 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 2/20 | 0.43 |
| ▸ | CCND1 | P24385 | 2/20 | 0.43 |
| ▸ | CDK9 | P50750 | 2/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.43 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25256048 | 0.88 | PIM1 (0.55) | PIM3PIM1CHEK1FLT3AKT1 | |
| SCHEMBL30484071 | 0.88 | PIM1 (0.55) | PIM3PIM1CHEK1FLT3AKT1 | |
| SCHEMBL14098810 | 0.78 | CDK4 (0.51) | PIM3CDK4CCND1CDK9CDK5 | |
| SCHEMBL30588977 | 0.77 | PARP1 (0.50) | CHEK1CDK4CCND1CDK5CDK5R1 | |
| SCHEMBL3123673 | 0.77 | PARP1 (0.50) | CHEK1CDK4CCND1CDK5CDK5R1 | |
| SCHEMBL25262254 | 0.75 | DYRK1A (0.46) | PIM3PIM1CHEK1FLT3AKT1 | |
| SCHEMBL23885373 | 0.74 | PDPK1 (0.50) | CDK4CCND1CDK9CDK5CAMK2A | |
| SCHEMBL9984239 | 0.74 | METAP2 (0.47) | PIM3PIM1CHEK1FLT3METAP2 | |
| SCHEMBL30051967 | 0.74 | PDPK1 (0.50) | CDK4CCND1CDK9CDK5CAMK2A | |
| SCHEMBL6881565 | 0.73 | EGFR (0.44) | CDK4CCND1CDK9CDK5CAMK2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366770-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE SWITZERLAND GMBH (CH) | 2024-11-07 | — | — | US | disclosed |
| EP-4457230-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BeiGene Switzerland GmbH (CH) | 2024-11-06 | — | — | EP | disclosed |
| CN-118414336-A | Degradation of Bruton Tyrosine Kinase (BTK) by conjugation of BTK inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2024-07-30 | — | — | CN | disclosed |
| WO-2023125907-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023125907-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2023-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366770-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | PIM3 783/4885PIM1 676/4885CHEK1 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.